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The Journal of Immunology
Enhancer Turnover Is Associated with a Divergent
Transcriptional Response to Glucocorticoid in Mouse and
Human Macrophages
Alasdair W. Jubb,*,†,1 Robert S. Young,*,1 David A. Hume,† and Wendy A. Bickmore*
Phenotypic differences between individuals and species are controlled in part through differences in expression of a relatively con-
served set of genes. Genes expressed in the immune system are subject to especially powerful selection. We have investigated the
evolution of both gene expression and candidate enhancers in human and mouse macrophages exposed to glucocorticoid (GC), a
regulator of innate immunity and an important therapeutic agent. Our analyses revealed a very limited overlap in the repertoire of
genes responsive to GC in human and mouse macrophages. Peaks of inducible binding of the GC receptor (GR) detected by chro-
matin immunoprecipitation-Seq correlated with induction, but not repression, of target genes in both species, occurred at distal
regulatory sites not promoters, and were strongly enriched for the consensus GR-binding motif. Turnover of GR binding between
mice and humans was associated with gain and loss of the motif. There was no detectable signal of positive selection at species-
specific GR binding sites, but clear evidence of purifying selection at the small number of conserved sites.We conclude that enhancer
divergence underlies the difference in transcriptional activation after GC treatment between mouse and humanmacrophages. Only
the shared inducible loci show evidence of selection, and therefore these loci may be important for the subset of responses to GC that
is shared between species. The Journal of Immunology, 2016, 196: 813–822.
T
he gene complements of different mammals are remark-
ably similar (1), which implies that phenotypic variation
is driven mainly by differences in transcriptional regula-
tion (2–4). Expression of orthologous genes can differ between
closely related primates (5) and even between individuals within a
species (6), with genes involved in extracellular processes and the
immune response being the most divergent (7). The most highly
conserved and highly inducible promoters are, paradoxically, the
most sensitive to variation in expression across species (8). Much
of this divergence is driven by the evolution of cis-regulatory el-
ements (9), such as enhancers (10).
Deep evolutionary conservation has been used to identify can-
didate enhancers (11, 12). Nevertheless, complete gain and loss of
enhancers between species are also common (13–15). In mam-
mals, at least, turnover of cis-regulatory elements can occur rap-
idly enough to be identified between strains of a single species
(16). Most evolutionarily labile enhancers can be aligned to the
genomes of distantly related species (17), suggesting that the ac-
quisition of novel enhancers can occur through mobilization of
existing sequences, including transposable elements (18). Species-
specific regulatory elements display a level of nucleotide diversity
consistent with a relaxation in evolutionary constraint (14). Be-
cause not all transcription factor binding sites have a direct effect
on gene expression (18–20), these sites may represent functionally
neutral sequence.
The profound differences in the immune systems of mice and
humans have long been recognized (8, 21–23), and are accom-
panied by both high levels of gene expression divergence and cis-
regulatory element turnover (7). This divergence is most likely
driven by the evolutionary pressure of host–pathogen interactions,
alongside changes in the expressed protein-coding sequences
driven by positive natural selection (24).
Glucocorticoids (GC) are powerful metabolic hormones that are
released in response to stress (25) and that provide natural feed-
back regulation of immune function. Exogenous GC are widely
used as anti-inflammatory therapy (26). Accordingly, their actions
on immune cells are likely to be affected by evolutionary selec-
tion. GC act by binding to an intracellular nuclear hormone re-
ceptor—the GC receptor (GR). Nuclear GR may bind directly to
DNA, classically as a homodimer (27), to a canonical glucocor-
ticoid response element (GRE), or may act indirectly by binding
other transcription factors such as NF-kB and AP-1 (28), as well
as by recruiting coregulators, for example, GRIP1 (29). Gene re-
pression by GC in inflammation has been linked to binding of
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negative GR-binding elements (nGRE) (30, 31), which are distinct
from the consensus GRE. Aside from their ability to repress the
actions of proinflammatory stimuli, GC alone act directly on
macrophages, producing changes in cell survival, proliferation,
morphology, and phagocytosis (32–35). In other cellular systems,
GR binds DNA mainly at cis-regulatory elements (36) and alters
chromatin organization (37–39).
We sought evidence of the evolutionary pressure on GC actions
by comparing the responses of human and mouse macrophages.
Only limited expression data for macrophages responding to GC
have been generated previously (40–42). We confirmed that the
majority of genes with a significant shift in expression in response
to GC are upregulated (36), but few target genes were shared
between the two species. GR binding sites were enriched near to
inducible genes in both species, and species-specific binding was
associated with species-specific upregulation of genes in the same
genomic region. However, these species-specific sites do not ap-
pear to be experiencing a selective pressure, and the only selection
we could detect was for the preservation of the small set of GR
binding sites that were shared between humans and mice.
Materials and Methods
Ethics
Procedures involving human volunteers were approved by the South East
Scotland National Health Service Research Ethics Committee. All vol-
unteers gave informed consent. Animals were cared for and managed within
the Roslin Institute’s guidelines for animal safety and welfare.
Cell culture
Eight- to 10-wk male wild-type C57BL/6 mice were culled by cervical
dislocation. Bone marrow was flushed from hind limbs and then cultured in
RPMI 1640 supplemented with penicillin/streptomycin, Glutamax (Invi-
trogen), and 10% FCS for 7 d in the presence of human rCSF-1 at 104 U/ml.
Human peripheral blood monocytes were isolated from blood samples by
Ficoll gradient separation of buffy coats, followed by MACS CD14+ve se-
lection (Miltenyi Biotec). They were then cultured as above for 7 d before
being treated as indicated with 100 nM dexamethasone (Sigma-Aldrich) or
ethanol vehicle.
RNA extraction and processing
RNAwas prepared using RNeasy column-based extraction with on-column
DNase treatment (Qiagen). RNA quality was checked using a 2100 Bio-
analyzer (Agilent). For quantitative RT-PCR (RT-qPCR), cDNA was pre-
pared using SuperscriptIII (Invitrogen). Relative expression was deter-
mined using SyBR Green on a LightCycler480 (Roche) and compared
with GAPDH as a reference. Primer sequences are given in Supplemental
Table 1G. For expression microarrays, RNA was prepared using standard
Affymetrix protocols and applied to the HT-MG430PM (mouse), or HT-
U33plusPM (human) chip by Edinburgh Genomics.
Chromatin immunoprecipitation
Abs used for chromatin immunoprecipitation of mouse GR were BuGR2 1
mg/106 cells (ThermoFisher/Pierce) and normal rabbit IgG sc-2025 (Santa
Cruz). For human GR chromatin immunoprecipitation (ChIP) we used
Sigma-Aldrich Imprint anti-GR, 1 mg/106 cells, and mouse IgG.
To prepare Ab-bound beads, 20 ml protein A Dynabeads (Invitrogen) per
immunoprecipitation (IP) were washed once and then diluted to 200 ml in
block solution (13 PBS, 0.5% BSA, and 2 ml 0.1 M PMSF). Ab was added
and rotated for 3 h at 4˚C.
Cells were washed gently once with PBS; cross-linked in tissue culture
plates with 1% formaldehyde/RPMI 1640 at room temperature for 10 min
(mouse) or 7.5 min (human); and then quenchedwith 0.125M glycine. Cells
were detached by scraping in PBS and then spun down (400 3 g, 5 min,
4˚C), resuspended, and counted. For bone marrow–derived macrophages in
mouse (mBMDM), 106 cells per IP were then lysed for 15 min on ice in
1% SDS, 10 mM EDTA, and 50 mM Tris-HCl (pH 8.1) supplemented with
protease inhibitors (Calbiochem), 1 mM DTT, and 0.2 mM PMSF (Sigma-
Aldrich). The solution was diluted in IP dilution buffer (0.1% Triton
X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl [pH 8.1]) and son-
icated using a Soniprep 150 to produce an average fragment size 300–500
bp. Chromatin was spun for 10 min at 10,000 3 g, 4˚C, and then sup-
plemented with 20% Triton X-100 1% and BSA (Sigma-Aldrich) to 50
mg/ml. Input aliquots were removed and stored at 220˚C. Chromatin was
then added to the Ab-bound protein A Dynabeads (Life Technologies) and
rotated overnight at 4˚C. Beads were washed three times for 10 min each in
1–1% IP dilution buffer, 2–1% Triton X-100/0.1% Na-deoxycholate/0.1%
SDS, 50 mM HEPES (pH 7.9), 500 mM NaCl, 1 mM EDTA and 3–0.5%
Na-deoxycholate/0.5% Nonidet P-40, 20 mM Tris-HCl (pH 8), 1 mM
EDTA, and 250 mM LiCl. Chromatin was extracted at 37˚C for 15 min on
a vibrating platform in 100 ml extraction buffer (0.1 M NaHCO3, 1%
SDS). To reverse cross-links, samples were supplemented to 300 mM with
NaCl, treated with 20 mg RNase A (Roche), and then incubated for ∼8 h at
65˚C. Proteinase K (40 mg; Genaxxon) was added, and samples were in-
cubated at 55˚C for 1 h. DNA was purified using the QIAquick PCR pu-
rification kit (Qiagen). Real-time quantitative PCR analysis to determined
percent input bound at known GR target loci was carried out on a Light-
Cycler 480 System using SYBR Green Master Mix (Roche). Primers used
are presented in Supplemental Table 1G. For sequencing ChIP DNA was
prepared and amplified using Illumina adapters and Tru-Seq multiplex
primers and then sequenced using a HiSeq2500 by Edinburgh Genomics.
For monocyte-derived macrophages in humans (hMDM), the same pro-
tocol was followed with the following differences. Due to constraints on
cell number for sequencing, material was prepared from four volunteers,
treated, fixed for 7.5 min, and lysed, as above. Consistency of the assay
was assessed by biological replicates of ChIP quantitative PCR for a
known GR target in the FKBP5 locus (Supplemental Fig. 2A). Chromatin
was sonicated to a fragment size of 400–600 bp, and the chromatin was
pooled, to give 25 3 106 cells in total. This was split into three for the IP
step and recombined at extraction. DNAwas then isolated as above, split
into three aliquots, and blunt ended with Klenow (Roche), polynucleo-
tide kinase (New England Biolabs), and T4 DNA polymerase (Roche).
An overhanging A base was added using Klenow (-exo) (New England
Biolabs) and Illumina adapters ligated overnight at 16˚C with T4 DNA
ligase (New England Biolabs). The IP samples were recombined after
ligation and then split again into seven aliquots. Libraries were amplified
from each of these aliquots using Illumina Tru-seq multiplex primers and
Phusion high-fidelity DNA polymerase (New England Biolabs), and the
resulting material was pooled and sequenced by Edinburgh Genomics on
a Hiseq-2500.
Data analysis
Expression data. Analysis was performed using R/Bioconductor packages
arrayQualityMetrics, affy, and limma (43–45). Expression values were
generated using rma. Further exploratory expression analysis used unlog-
ged expression values prefiltered for low expressed probe sets as input for
the graphical correlation-based tool Biolayout Express3D (46). A range of
correlation coefficients and Markov Cluster Algorithm values was used to
determine an optimal graph structure from which clusters of genes were
then read. Clusters were then manually curated to remove artifacts. Genes
from these lists were selected across a range of fold changes for analysis by
RT-qPCR and a threshold drawn at log2 fold change = 1, where all tested
genes were confirmed (Supplemental Fig. 1A, 1B). To limit loss of genes
with extreme profiles—and hence less likely to cluster—genes reaching
log2 fold change .1.5 using a conventional analysis by log fold change
were also retained if the corresponding expression profile was consistent
with a response across all replicates. Orthologs were identified using the
Human Genome Organisation Gene Nomenclature Committee Comparison
of Orthology Predictions tool (47).
Promoter analysis
Promoters were defined as 2300, +100 bp of the transcription start sites
(TSS) described by the FANTOM5 Consortium (48). Where multiple TSS
are known, any overlaps were concatenated. Average sequence conserva-
tion scores (phastCons) for promoter regions were extracted, and enriched
motifs were identified using HOMER (49).
Comparison to genome-wide association study results and
inflammatory genes
The genome-wide association study (GWAS) catalog (50) (http://www.
genome.gov/gwastudies/) was manually edited to retain only hits with
association to inflammatory/immune conditions (Supplemental Table IH,
1408 unique single-nucleotide polymorphisms [SNPs]). The intersection
of reported genes was assessed by fold change above a background dis-
tribution generated using permutation (100,000) of random gene sets.
Significance of the difference was assessed using Pearson’s x2 test.
The intersection of risk SNPs and promoters was ascertained using
BEDtools (51).
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Lists of functional terms from multiple publically available databases were
generated using HOMER (49), filtered using a threshold of 2log p value
6.5, and then manually curated to remove duplicate terms.
ChIP sequencing
Sequencing quality was assessed with FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc), and sequence from adapters was removed
using trimmomatic (52). Paired end reads were aligned to mm9 or hg19
by Bowtie2 (53) using default options (-D 15 -R 2 -L 22 -i S,1,1.15).
Downstream analysis was performed using HOMER (49), including cre-
ation of bedGraph files for visualization, peak calling, and annotation.
Peaks were called by comparison with the sequenced input sample for each
experiment as a measure of background. For the mBMDM data after
confirming congruence (86% peak overlap), data from two independent
replicates were combined. Publically available sequencing data for compari-
sons were accessed via the National Center for Biotechnology Information
Gene Expression Omnibus for Uhlenhaut et al. (40) (GSE31796) and
Ostuni et al. (54) (GSE38379).
We compared the number of observed intersections of our GR bound sites
with sites of PU.1 binding, H3K4me1, H3K4me3, H3K27ac, and FAIRE-seq
reported in unstimulated mBMDM (54) to the median intersection that oc-
curred in 1000 genome-permuted GR peak locations. Counts of intersections for
all marks were generated using HOMER (mergePeaks 2cobound 2d given).
To compare the locations of GC-regulated genes with GR peaks, we
calculated the proportion of peaks within a given genomic interval from the
TSS of a regulated gene (Fig. 3A, 3B). We calculated the enrichment of GR
peaks near to regulated genes as the ratio of the proportion of regulated
genes near to a GR peak to the proportion of unregulated genes with a GR
peak within the same genomic interval. The significance of both these
results was estimated by comparing them to the 95% confidence interval of
1000 replicates of genome-permuted GR peak locations.
We compared peaks between species using liftOver provided by University
of California, Santa Cruz (UCSC) to get the coordinates of those peaks falling
within syntenic blocks. Peaks with .1-bp overlap were assigned as shared.
Insertions and deletions were called by comparison with dog (CanFam2),
horse (EquCab2), cow (BosTau6), and pig (SuScr3) genomes. If the sequence
underlying a peak could be aligned to at least one of these species, the peak
was defined as being deleted; if not, then it was called an insertion. Human
GR sites were assigned as deletions in along the mouse lineage (Fig. 2).
Where multiple orthologs were present, this analysis was run “all to all.”
The role of species-specific GR binding was assessed by calculating the
proportion of genes with GR binding within 1 Mb that were upregulated to the
proportion of all genes that were upregulated. These ratios were calculated
separately for each combination of shared, mouse-specific, and human-specific
GR peaks and upregulated genes (Fig. 4). Significance of the difference be-
tween mouse- and human-specific binding was assessed using Pearson’s x2.
To compare the enrichment of motifs in shared versus aligned nonbound
peaks, we performed motif finding using HOMER as above, using the
nonbound as background.
Genomic evolutionary rate profiling (GERP) scores for the locations
of bound GR motifs in both humans and mice were extracted from the
UCSC genome browser. These scores have been calculated by running the
GERP++ algorithm on the 36-way mammalian genome alignments (55).
Data access
Microarray and sequencing data presented in this paper have been submitted
to the National Center for Biotechnology Information Gene Expression Om-
nibus (http://www.ncbi.nlm.nih.gov/geo/), accession GSE61881. Publically
available sequencing data for comparisons were accessed via the National
Center for Biotechnology Information Gene Expression Omnibus for
Uhlenhaut et al. (40) (GSE31796) and Ostuni et al. (54) (GSE38379).
Results
Glucocorticoid-induced gene expression in macrophages
The response to GC was determined by gene expression profiling,
using the most commonly used models of macrophage biology,
mBMDM, and hMDM, both cultivated in vitro using the macro-
phage growth factor, CSF1 (56–58), as used in a previous com-
parison of the response to LPS (8).
To identify both initial direct targets and downstream secondary
consequences, gene expression was measured at six time points
over 24 h following treatment with dexamethasone. After filtering
for low expressed and low variance probes, lists of regulated genes
were confirmed by RT-qPCR (see Materials and Methods and
Supplemental Fig. 1A, 1B) to produce a high confidence set. For
mBMDM there were 160 induced and 50 repressed genes over the
full 24-h time series. In the hMDM, 225 genes were induced and 125
repressed (Fig. 1A, 1B; full lists are presented in Supplemental
Tables 1A, 1B). In both species, induced genes responded more
quickly than repressed genes: in mBMDM, 10, 32, and 62% within 1,
2, and 4 h, respectively, compared with the repressed gene set (0, 4,
and 14% at the same time points). The equivalent figures for hMDM
were 11, 30, and 70% induced within 1, 2, and 4 h, respectively (2,
14, and 47% for the repressed set at the same time points).
For mBMDM and hMDM, the robust induced gene set included
several knownGR targets [e.g., Dusp1, Tsc22d3, Fkbp5 (40), and Per1
(36)]. As expected from earlier studies of mBMDM (59), both re-
pressed gene lists contained urokinase plasminogen activator (Plau)
(60). Because Plau is a target of sustained MAPK signaling (60), its
repression may be an indirect consequence of the induction of the
MAPK inhibitor Dusp1. In mBMDM, eight annotated transcription
factors were among the induced gene set, including four (Fos,
Hivep2, Klf4, Ncoa5) that were induced within 2 h and that could
contribute to the downstream regulatory cascade. Similarly, 10 tran-
scription factors were induced and 2 repressed within 2 h in hMDM
(Supplemental Table IC). Functional annotation revealed a number of
terms shared by the induced sets in both species, including stimulus
response, immune/wounding response, and regulation of transcription
(Supplemental Fig. 1C). The terms nuclear processes, apoptosis, and
development were enriched in the early-induced set; cell surface
immune response, phagocytosis, migration, and cytoskeleton were
found among the late responders in mBMDM. Functional annotation
of induced genes from hMDM revealed terms absent from the mouse
data set, including the following: adipogenesis, FOXO and insulin
signaling, and MAPK cascade. The terms immune pathways, IL-10
production, NF-kB, TNF, NOD-like receptor, and rheumatoid arthritis
were enriched in the hMDM-repressed set (Supplemental Fig. 1C).
Genes regulated by GC in human macrophages are candidates
for involvement in inflammatory and metabolic disease. Indeed,
among GC-regulated genes in hMDM there was a 3.7-fold en-
richment of genes reported to have a genetic association with an
inflammatory condition or metabolic disease (n = 48, x2, p = 1.13
1025; Supplemental Tables 1D, 1H) in the GWAS catalog (50). In
mBMDM, only three of these genes were upregulated following
GC treatment (Fos, Mertk, and Tlr7).
GC gene induction in hMDM differs from mBMDM
A total of 228 mouse orthologs for the 225 GC-induced hMDM genes
and 131 orthologs for 125 repressed genes was identified (seeMaterials
and Methods). The reciprocal analysis found 157 human orthologs of
160 mBMDM-induced and 55 orthologs of 50 mBMDM-repressed
genes. From among this set of robustly regulated genes, 33 induced
and 3 repressed genes were shared by the two species (Supplemental
Table IE), a small but significant overlap (p = 4 3 10215, cumulative
binomial probability). The magnitude of expression change between
genes upregulated in both species compared with the complete set of
upregulated genes was only marginally different, being greater for the
mouse genes (1.4-fold enrichment, Wilcoxon rank sum, p = 93 1024).
Promoters of genes induced by GC in hMDM and mBMDM are
conserved
Despite their discordant regulation between the species, and in contrast
to the situation for the response of macrophages to LPS (8), the
promoter regions of GC-inducible genes were conserved (Fig. 1C–E).
The genes that had a shared response did not have significantly higher
promoter conservation (p = 0.166 and p = 0.3117 compared with
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human specific and mouse specific, respectively; Wilcoxon rank sum)
(Fig. 1C). In each species, promoters of genes that were induced the
most rapidly to GC were more highly conserved than those with a
slower response or than for genes whose expression was repressed in
response to GC (Fig. 1D, 1E).
Analysis of the promoters (2300 bp, +100 bp of the TSS defined
previously by capped analysis of gene expression analysis) (48) of
GC-regulated genes for transcription factor-binding motifs provided
no evidence of enrichment for GREs, and few motifs were even
marginally enriched in the induced gene sets (analysis not shown).
GR binding occurs at canonical GRE sites in distal enhancers
To identify the sites involved in the GC response in the two species,
chromatin immunoprecipitation for GR and sequencing (ChIP-seq)
was performed 2 h after dexamethasone treatment in both mBMDM
and hMDM. Representative UCSC browser tracks for GR binding in
mBMDM and hMDM are shown in Fig. 2A and 2C.
There were 488 high-confidence GR-binding peaks in chro-
matin from mBMDM, most (474) of which were induced by
dexamethasone. These peaks lie away from promoters, in intergenic
regions and introns (Supplemental Fig. 2B). Based upon de novo
motif finding, the majority (78%) of the GR peaks contained a
motif, or motifs, closely resembling the GRE within 625 bp of the
peak center. This figure rises to 86% when considering a region 6
100 bp from the peak center (Fig. 2B). There were no matches
under the GR peaks for the nGRE [CTCC(n)0-2GGAGA, where
(n)0-2 indicates flexibility in spacing] (30). A more permissive
search revealed 59 of 488 peaks containing a weak match for
FIGURE 1. The expression response of macrophages to dexamethasone is divergent despite target gene promoter sequence conservation. (A) For each
time point studied, heatmaps of genes regulated by 100 nM dexamethasone in hMDM alongside the orthologous genes from mouse and their expression
values in mBMDM with height proportional to the number of genes changing (red = induced, blue = repressed). (B) The inverse analysis to that in (A)
showing genes regulated in mBMDM by 100 nM dexamethasone alongside their human orthologs. (C) Box plots showing average sequence conservation
scores (phastCons) of promoters for (all Hs) all human genes, genes responding only in either hMDM (Hs specific) or mBMDM (Mm specific) and genes
with a shared expression response (shared). (D and E), as in (C), but for all genes regulated by GC in (D) mBMDM and (E) hMDM, categorized by response
and kinetics. All Refseq promoters are shown as a measure of background (***p , 1 3 10210, **p , 1 3 1024, *p , 0.05, Wilcoxon rank sum; n =
number of promoters; median = horizontal bar, whiskers = 1.53 interquartile range, statistical comparisons are made to background).
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nGRE. Of these, only 4 have a repressed gene within 1 Mb (Plau,
Egr2, Rgs2, Cy2s1), one of which has a prominent canonical GRE-
containing peak at 74 kb (Rgs2).
In hMDM treated with dexamethasone, 484 high-confidence GR
peaks were detected (Fig. 2C). As in the mouse data, these were
remote from promoters in noncoding regions of the genome
(Supplemental Fig. 2B) and were highly enriched for a motif closely
matching the consensus GRE (52% within 625 bp, 62% within 6
100 bp) (Fig. 2D, Supplemental Table 2B), but not for the nGRE.
None of the inflammation-associated SNPs from the GWAS catalog
identified above (Supplemental Table IG) directly overlap with GR-
bound peaks in hMDM, although two lie within 350 bp (rs10499197,
near TNFAIP3 linked to systemic lupus erythematosus and systemic
sclerosis and rs12466022, linked to multiple sclerosis).
Inducible transcription factors often bind to regions that are
already in open chromatin. The GR peaks in mBMDMwere clearly
associated with sites marked by various enhancer-associated his-
tone marks in unstimulated cells (Supplemental Fig. 2C). Overall,
462 of 488 (94%) of our sites overlap with one or more enhancer
marks (Supplemental Fig. 2C), and individual marks also showed
enrichments above genome-wide expectations (H3K27ac [70.3%,
24.5-fold enriched, p , 2.2 3 10216], H3K4me1 [90.4%, 18.4-
fold enriched, p , 2.2 3 10216]) and open chromatin (43.4%,
53.9-fold enriched, p , 2.2 3 10216). The E26 transformation-spe-
cific (ETS) factor PU.1 is a master regulator of macrophage
transcription, and other stimulus-induced transcription factors
have been shown to bind at enhancers marked by PU.1 in activated
macrophages (49, 61). The sites recruiting GR after dexametha-
sone treatment also show significant overlap with PU.1 binding
sites in unstimulated mBMDM (72.3%, 32.1-fold enriched, p ,
2.23 10216 Pearson’s x2; Supplemental Fig. 1C). Overall, a close
match to the PU.1 consensus motif was found in 36% of GR-
bound sites in mBMDM (Fig. 2B, p = 1 3 10279), and 76%
had an ETS motif. Similarly, 34% of GR peaks in treated hMDM
had a PU.1 motif (Fig. 2D, p = 1 3 10236) and 62% an ETS
factor-binding motif. The GRE and ETS sites were closely spaced
FIGURE 2. GR binding in mBMDM and hMDM occurs at sites with the canonical GRE. (A) ChIP-seq data tracks from the UCSC browser for the Fos–
Jdp2 region, for GR binding in mBMDM. Data from ChIP with anti-GR Abs after treatment with 100 nM dexamethasone for 2 h (Dex GR IP), input
material (Dex input), and immunoprecipitated material from a vehicle-treated control (Vehicle GR IP) are shown. (C) As in (A), but for FOS–JDP2 in
hMDM. Vehicle GR IP data were not generated in hMDM due to constraints on available cell numbers. A GR-bound site that aligns between mBMDM and
hDMD is highlighted in green. Alignments are to mm9 and hg19 versions of the mouse and human genomes, respectively. (B and D) Enriched motifs found
de novo within GR-bound sites in mBMDM (B) and hMDM (D). (E) Evolutionary outcomes for GR peaks in human. Aligned sites where the orthologous
region is bound by GR in mice are shown in green and in yellow if the site is not bound by GR in mice. Sites that could not be aligned are defined as either
insertions (purple) or deletions (red) by comparison with dog (CanFam2), horse (EquCab2), cow (BosTau6), and pig (SuScr3) genomes (see Materials and
Methods). Human GR sites were assigned as deletions in the mouse lineage.
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(average of 40 bp between the motifs in mice and 43 bp in hu-
mans), suggestive of cooperativity between ETS factors and GR
binding. Aside from PU.1, there was little similarity in other
transcription factor motifs enriched around the GR peaks in the
two species. For the mouse, other enriched motifs include those
that can bind Cepb, AP-1, c-Jun, and Runx1 (Fig. 2B). For the
hMDM data set, IFN regulatory factor 4 and RXR sites were the
most significantly enriched (Fig. 2D).
GR binding differs in hMDM and mBMDM
The majority of GR-bound sites can be aligned between humans
and mice (n = 274 [56.6%] and 354 [79.2%] in humans and mice,
respectively), but only a minority of these (n = 32) are bound by
GR in both (Fig. 2E, Supplemental Table 1F). There was no dif-
ference between the rate of turnover of GR binding in evolution at
these sites in humans and mice (x2, p = 0.18). Sites that could not
be aligned between humans and mice were defined as de novo
insertions if they could not be aligned to any of several outgroup
species, or deletions if they could be (see Materials and Methods).
As previously reported (62), there was an increased rate of dele-
tions along the mouse lineage (3.8-fold, x2, p = 2.6 3 10211) and
a smaller, but significant, 1.6-fold increased rate of insertions
along the human lineage (x2, p = 2.0 3 1023). There have been
several reports that transposable elements are the source of
species-specific sequences (14, 63). Indeed, transposable elements
were the source of almost all inserted GR-binding sequence (96.6
and 75.5% in humans and mice, respectively), which represent
1.8- and 1.4-fold enrichments (x2, p, 7.63 1023) over the deleted
sequences in humans and mice, respectively.
GR binding is associated with induced genes in both human
and mouse macrophages, but the target loci are not conserved
There was a clear association between GR-binding peaks and
the loci encoding GC-induced genes in both human and mouse
macrophages. This enrichment was greatest at 10 kb from the TSS,
but still marginally detectable at 1 Mb in both species (Fig. 3). In
A549 cells, GR has been reported to be bound closer to induced
genes than to repressed genes (36), whereas in our macrophage
data, there was no detectable relationship between GR-binding
peaks and repressed genes (Fig. 3).
The expression response to GC was stronger where there were
multiple GR peaks within 200 kb of the TSS of an induced gene
than if there was only a single site (mBMDM, 1.7-fold median
log2 fold change, p = 0.0018; hMDM, 1.4-fold median log2 fold
change, p = 0.031, Wilcoxon rank sum). Early (,2 h) induction
was not associated with greater proximity to a GR peak (Wilcoxon
rank sum, p = 0.20 and p = 0.16, for humans and mice, respec-
tively).
As stated above, among the set of GR-bound sites from hMDM
and mBMDM that can be assigned to regions of conserved DNA,
only a minority (n = 32) were clearly conserved in binding
(Supplemental Table IF). Sixteen of the conserved GR sites are
adjacent to genes that were induced in both species and that en-
code known regulators of the inflammatory response (e.g.,
DUSP1, FKBP5, MAP3K6, TSC22D3, FOS [Fig. 2A, 2C],
KLF4). Even at these conserved loci, GR binding differed: a
previously described proximal peak at the DUSP1/Dusp1 locus
was retained (64), but the strongest binding site was not shared
(Fig. 4A). Overall, genes that were induced in both species were
enriched for having GR bound within 1 Mb—but not necessarily
at orthologous positions—in both species (4.0-fold enrichment,
x2, p = 2.9 3 1027; Fig. 4A).
The more common pattern was for GR binding at regulated loci
to be divergent between the species; for example, the GR peak
upstream of F13a1, a component of the coagulation cascade, is
mouse specific (Fig. 4C, expanded view in Supplemental Fig. 2D).
Genes like F13a1 that responded to GC only in mouse were 2.0-
fold enriched over human-specific genes for GR binding within
1 Mb in the mouse (x2, p = 0.0011; Fig. 4D). Similarly, human-
specific GR binding was enriched adjacent to human-specific GC-
regulated genes. For example, ADORA3, which has a known role
in driving the human macrophage phenotype (65), has an intronic
GR peak that is not present in mouse. As for the mouse, there
was an overall 1.7-fold enrichment for a human-specific GR
FIGURE 3. Induced genes are associated with GR
binding. (A and B) The proportion of GR ChIP peaks
with induced (green line) or repressed (red line) gene
promoters within a given genomic distance for (A)
mBMDM and (B) hMDM. The 95% confidence intervals
from matched genome-permuted distributions of GR
peaks are shown in gray. (C and D) Enrichment of the
proportion of induced (green line) gene promoters with a
GR peak within a given interval versus the proportion of
induced genes without a GR peak (red line) within that
interval for (C) mBMDM and (D) hMDM. No enrich-
ment is seen for repressed genes (shown in red). The
95% confidence interval from a genome-permuted dis-
tribution of GR peaks is shown in gray.
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peak within 1 Mb genes that were specifically upregulated in
human macrophages (x2, p = 0.034; Fig. 4E, 4F, expanded
view in Supplemental Fig. 2D). These data highlight the strong
correlation between divergent GR binding and divergent gene
expression response to dexamethasone across species (Figs. 1,
2), and the shared enrichment for GR binding in the vicinity of
genes that were induced in both species (Fig. 3). We conclude
that the turnover of GR binding sites between humans and
mice is the primary driver of the divergent transcriptional re-
sponse to GC.
FIGURE 4. GR binding sites are minimally conserved between mice and humans, and this is linked to the divergent transcriptional response to GC. (A) GR
ChIP-seq data from mBMDM (orange) and hMDM (cyan) showing conserved GR binding (green highlight) at a locus (DUSP1/Dusp1) whose expression is rapidly
induced by GC in both mouse and human macrophages. GR-bound sites aligned between species are linked by light green highlight: the most prominent sites are
bound in only one species. (B) Enrichment/Depletion for mouse/human shared GR binding within 1 Mb for GC-responsive genes that are shared between mice and
humans (green), mouse specific (cyan) and human specific (orange). Numbers give raw counts for each category. (C) As in (A), but showing mouse-specific GR
binding at F13a1/F13A1, which is induced in mBMDM, but not hMDM. (D) As for (B), but for mouse-specific GR binding sites. The x2 p value for the difference
between mouse- and human-specific sites is given. (E) As in (A), but showing human-specific GR binding at ADORA3/Adora3, which is induced in hMDM, but not
mBMDM. (F) As for (D), but for human-specific GR binding sites. Expanded windows for F13A1 and Adora3 are shown in Supplemental Fig. 1D.
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Most of the species-specific GR sites are in genomic regions that
can be aligned between mice and humans (Fig. 2E), suggesting
that the changes that cause motif loss occurred as a result of nucle-
otide substitutions and deletions, rather than insertion or deletion of
sequence. Loss of GR binding was associated with loss of the GRE
motif. Among aligning sequence, there was significant enrichment
for the GRE motif in the subset that is bound in both species com-
pared with those that are species specific (Fig. 5). This is also true for
PU.1, although less strongly, reflecting the lower enrichment for this
motif in the baseline data set. Consistent with the loss of GR binding,
there was depletion for the GRE motif in locations that were not
bound by GR, even when the orthologous location in the opposite
species was bound (Supplemental Fig. 3A, 3B). There was some
enrichment for PU.1 in human sequence orthologous to mouse-
specific sites, which suggests there may be some residual regulato-
ry function in macrophages at these sites.
The turnover of the GRE motif at species-specific GR peaks could
be driven by a selective pressure on the immune response to modulate
host–pathogen interactions (8, 23). Evolutionary constraint was de-
tectable around the shared sites in each species (Fig. 5C, 5D), ex-
tending to ∼100 bp beyond the motif (Supplemental Fig. 3C, 3D).
This implies that purifying selection has acted to preserve this motif
between humans and mice. As predicted by the degeneracy of the
GRE motif, evidence of selection was reduced in the center of the
motif. However, within the species-specific GR binding sites, there
was no signature consistent with substantial selection across the motif
(Fig. 5C, 5D). Indeed, there was some slight constraint at the non-
degenerate sites in the motif. This suggests that turnover of the GRE
motif at individual loci is driven by nucleotide substitutions at ap-
proximately the genome-wide mutation rate and not by positive se-
lection driving the gain or loss of new binding sites (Fig. 4).
Discussion
This study shows that the divergence of the transcriptional re-
sponse to GC in mouse and human macrophages is associated with
evolutionary turnover of candidate enhancers. These enhancers
contain canonical inverted repeat GRE and are bound by GR in
glucocorticoid-treated macrophages. Although GC have commonly
been studied as repressors of inflammatory gene expression, the
data indicate that, in the context studied in this work, GC act on
macrophages primarily as inducers of gene expression when
measured at the level of stable mRNA. The induced targets are
largely distinct between humans and mice (Fig. 1). This adds to the
weight of evidence that caution must be exercised when trans-
lating mouse findings to humans (8, 21, 22).
Repressed genes have been shown to lie further from GR-bound
sites than induced genes at candidate loci (66) and in previously
published ChIP-seq data from A549 lung epithelial cancer cell
line (36). Based upon genome-wide comparison, the genes re-
pressed after GC treatment in macrophages had no significant
genomic association with direct GR–DNA binding in either spe-
cies (Fig. 3), nor was there any support for the existence of nGRE
(30, 31) in either mouse or human GR ChIP-seq data sets. Lower
binding affinity and faster turnover time could compromise their
detection under the conditions we employed. Alternatively, there
may be context-dependent use of different types of regulatory
element. For example, the nGRE may only be relevant in mac-
rophages when GR acts to suppress inflammatory gene induction
(40), rather than in the basal CSF1-dependent state we have ex-
amined. The GC-responsive GR elements we identified were often
associated with binding motifs for the macrophage master tran-
scription factor PU.1. Therefore, as for other transcription factors
downstream of extracellular signaling (49, 54), the GR-binding
landscape is shaped by enhancer elements already occupied by
PU.1.
Evolutionary conservation has long been used to identify can-
didate functional regions of the genome (67). A very small subset
of GC-induced genes and nearby GR-bound sites fits this pattern.
These genes are enriched for a number of shared functional an-
notations, such as stimulus response and immune/wounding re-
sponse (Supplemental Fig. 1C), whereas the shared GR sites were
found near to induced genes in both species (Figs. 3, 4). The
shared GR-bound sites were subject to evolutionary constraint of
the GR-binding motif (Fig. 5), suggesting they have been exposed
FIGURE 5. Conserved GR binding is linked to conservation of the GRE. (A) Motif enrichment for the sites bound by GR in mBMDM that aligned and
were also bound in hMDM, using as background the mouse sites that could be aligned to human, but were not bound in hMDM (q values shown, Benjamini-
Hochberg). (B) Analogous to (A), but for hMDM sites bound in mBMDM versus sites that could be aligned, but were not bound in mBMDM. (C) Mean per
base constraint scores calculated using GERP (55) across the GRE in shared (green) and species-specific (red) peaks found in hMDM, where the gray bars
represent the SEM. Vertical dashed lines delineate the center NNN for the GRE, as derived de novo from our hMDM data. (D) Analogous to (C) for GR-
bound peaks and GRE motif found in mBMDM.
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to purifying selection to maintain their function in humans and
mice.
The large majority of the GR-bound sites were not conserved
between mice and humans. The level of divergence we found
between GR binding sites and motifs between human and mouse
macrophages is greater than that previously reported for a set of
liver-specific transcription factors, in which 20–30% of sites were
conserved between primates and rodents (13). Although our data
set is limited to one factor and motif, it would appear that GC-
responsive elements are even more divergent than the sites iden-
tified in liver, which would be consistent with previous observa-
tions for high divergence in long-range regulatory elements active
in immune tissues (7).
The gain or loss of these GR-bound sites is largely due to nu-
cleotide substitutions, rather than insertion or deletion of sequence
(Fig. 2), as previously reported for a set of liver enhancers (17).
These substitutions cause gain or loss of the canonical GRE as
well as partner motifs such as PU.1 (Fig. 5). These turnover events
had a biological consequence: they were clearly associated with
species differences in transcriptional regulation (Fig. 4C–F). The
macrophage subtypes studied in this work are not directly com-
parable, and there are known species differences in the response to
CSF1, which produces a proatherogenic signal in human macro-
phages, but not in mice (58). However, the association with se-
quence turnover strongly suggests that the divergent expression
response to GC is unrelated to the differences in the regulatory
network of different macrophage populations (68). Sequence
variation also underlies the divergent response of macrophages to
LPS, but in that case it was attributable to promoter sequence
variation (8).
There was no clear evidence for selection at species-specific GR
sites, which show functional turnover between humans and mice
(Fig. 5C, 5D). Some of these sites may be under lineage-specific
selection, in the same way that LPS-responsive genes are shared
by large animals (humans and pigs) but radically different in ro-
dents (8, 69). Such variation would not be detectable with the
available genomic sequence data. Alternatively, the associated
species-specific inducible genes may not have any function in the
feedback regulation of innate immunity. Some of the species-
specific GR-bound peaks might have arisen by chance within re-
gions that favor open chromatin in macrophages, and bind GR
solely as a consequence of high transcription factor concentrations
in the nucleus (70).
An interesting avenue for further research will be the physio-
logical consequences of the functional genomic changes that we
have found. We cannot say from our study how the genomic
changes are related to the substantial phenotypic differences be-
tween species, or how much effect change at any one locus might
have. One way to begin to address this would be, at a locus that
normally only responds to GC in humans, to insert the sequence of
the human GRE at the equivalent position in the mouse genome and
compare the response.
The general principles of the macrophage response to GC are
strongly conserved between mice and humans, but the specific loci
involved have diverged considerably. As previously reported (13,
71), we have shown large-scale turnover of candidate enhancers
and have extended this work by demonstrating that these turnover
events impact on inducible gene expression. Surprisingly, given
the divergence at cis-regulatory sequence associated with immu-
nity (7) and the potential drive of host–pathogen interactions on
macrophages, we could not detect evidence of positive selection at
species-specific GR-bound sites. Conserved elements, in contrast,
showed clear evidence of selection to preserve their characteristic
motifs. Despite much interest in the turnover of enhancers (72),
the traditional approach of identifying regulatory elements through
deep evolutionary conservation may still be most useful in identi-
fying those sites associated with conserved gene regulation.
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